Abeona Therapeutics Inc vs Archer Aviation Inc — how do they compare? Abeona Therapeutics Inc trades at $6.63 (market cap $425.47M), while Archer Aviation Inc trades at $6.4 (market cap $4.84B). The key difference: Archer Aviation Inc is far larger — about 11.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ACHR | |
|---|---|---|
Market Cap | $425.47M | $4.84B |
Sector | Health | Industrials |
52-Week High | $7.46 | $13.64 |
52-Week Low | $4.17 | $4.44 |
Enterprise Value | $280.37M | $3.41B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Archer Aviation (ACHR) trades at $6.29, up 0.48% with strong technical momentum and bullish analyst sentiment. The company reported Q2 2026 revenue of $5 million, beating expectations by 150%, while announcing a transformative Boeing deal acquiring three businesses for a 20% equity stake. Despite negative profitability metrics and substantial cash burn, the strategic expansion into defense and autonomous aviation technology has driven recent stock appreciation.
The outlook remains speculative with significant execution risks, but strategic partnerships and regulatory progress provide potential upside. Investors face dilution concerns from the $750 million equity offering while betting on long-term commercialization of air taxi technology. The stock's valuation appears stretched with P/S ratio of 719.85, requiring successful commercialization to justify current levels.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →